Long-Term Risks of Mortality and Hospitalization Associated with Clozapine Use in Patients with Schizophrenia

Clozapine demonstrates exceptional efficacy in alleviating psychiatric symptoms in patients with treatment-resistant schizophrenia (TRS) and is the only medication approved by the U.S. Food and Drug Administration for this condition. However, its use is frequently postponed due to concerns about severe and potentially life-threatening side effects. This study employs between-individual and within-individual designs separately to investigate the long-term risks of mortality and hospitalization linked to clozapine use in individuals diagnosed with schizophrenia. By examining adverse outcomes, the research aims to enhance understanding of clozapine’s safety profile compared to other antipsychotics. The findings are intended to inform clinical practices and assist healthcare providers in making evidence-based decisions regarding clozapine treatment for schizophrenia management.